UnknownNot Applicable

Patient-Derived Xenografts to Reduce Cancer Health Disparities

United States500 participantsStarted 2019-11-12

Plain-language summary

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

Who can participate

Age range21 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer) * Signed informed consent that will be put on file Exclusion Criteria: * No informed consent obtained * Specimen unacceptable/degraded/etc. * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * Adults unable to consent

What they're measuring

Establish and characterize at least 200 patient-derived cancer xenografts (PDXs)

Timeframe: Up to 4 years

Trial details

NCT IDNCT04410302

SponsorUniversity of California, Davis

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06

View on ClinicalTrials.gov More Bladder Carcinoma trials